Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: A phase i study in chronic lymphocytic leukemia∗

Leukemia and Lymphoma

Volumn 57, Issue 4, 2016, Pages 803-811

  Kalaycio, Matt E ^a   George Negrea, O ^b   Allen, Steven L ^c   Rai, Kanti R ^c   Abbasi, Rashid M ^d   Horne, Heather ^e   Wegener, William A ^e   Goldenberg, David M ^e  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Low Country Cancer Care   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d Hematology Oncology Specialists   (United States)

^e IMMUNOMEDICS INC   (United States)

Author keywords

Antibody; CD20; chronic lymphocytic leukemia; subcutaneous therapy; veltuzumab

Indexed keywords

VELTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; ATRIAL FIBRILLATION; BACTERIAL MENINGITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DIVERTICULITIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LOW DRUG DOSE; MALARIA; MALE; MALIGNANT HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NIGHT SWEAT; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RIGOR; SINUSITIS; SURVIVAL RATE; SURVIVAL TIME; TOOTH INFECTION; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; AGED; CANCER STAGING; CLINICAL TRIAL; DRUG MONITORING; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETREATMENT; TREATMENT OUTCOME;

EID: 84961054916     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1085531     Document Type: Article

References (30)

1. Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010; 47: 156-169.
2. Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control 2012; 19: 110-118.
3. Nahas MR, Arnason JE. Targeting CD20 in chronic lymphocytic leukemia. Blood Lymphatic Cancer: Targets Therapy 2015; 5: 43-53.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
5. Keating MJ, OBrien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000; 27: 86-90.
6. OBrien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170.
7. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19: 2153-2164.
8. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-Agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755.
9. Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014; 124: 2196-2202.
10. Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16: 4331-4338.
11. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
12. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet 2015; 385: 1873-1883.
13. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
14. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
15. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkins lymphoma. Clin Cancer Res 2004; 10: 2868-2878.
16. Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113: 1062-1070.
17. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab, a novel humanized anti-CD20 monoclonal antibody: Characterization, current clinical results, and future prospects. Leuk Lymphoma 2010; 51: 747-755.
18. Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkins lymphoma: phase I/II results. J Clin Oncol 2009; 27: 3346-3353.
19. Leveque D. Subcutaneous administration of anticancer agents. Anticancer Res 2014; 34: 1579-1586.
20. Negrea GO, Elstrom R, Allen SL, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkins lymphoma. Haematologica 2011; 96: 567-573.
21. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
22. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
23. Karlsson C, Lundin J, Kimby E, et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009; 144: 78-85.
24. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004; 172: 3280-3288.
25. Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188: 3532-3541.
26. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177: 7435-7443.
27. Aue G, Lindorfer MA, Beum PV, et al. Fractionated subcutaneous rituximab is well-Tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010; 95: 329-332.
28. Lindorfer MA, Wiestner A, Zent CS, et al. Monoclonal antibody (mAb)-based cancer therapy: is it time to reevaluate dosing strategies? Oncoimmunology 2012; 1: 959-961.
29. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
30. Byrd JC, Brown JR, OBrien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.